Amato Malena, Esmaeli Bita, Ahmadi M Amir, Tehrani Mehdi H, Gershenwald Jeffrey, Ross Merrick, Holds John, Delpassand Ebrahim
Section of Ophthalmology, Department of Plastic Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, U.S.A.
Ophthalmic Plast Reconstr Surg. 2003 Mar;19(2):102-6. doi: 10.1097/01.IOP.0000056146.62409.24.
To determine the feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes (SLNs) in patients with conjunctival and periocular skin tumors and to determine the patterns of lymphatic drainage from such tumors.
We retrospectively reviewed the records of all patients with biopsy-confirmed conjunctival and periocular skin malignancies who underwent lymphoscintigraphy with or without SLN biopsy between January 1999 and June 2000. Patients underwent lymphoscintigraphy with 0.3 to 1 mCi of technetium Tc-99m sulfur colloid in a volume of either 0.2 mL or 1 mL. Images were taken as soon as the first SLNs were detected through the camera and every 15 minutes thereafter. Intraoperative mapping and SLN biopsy was performed 1 to 2 days after lymphoscintigraphy unless the patient refused or there were medical contraindications to the procedure.
The study included 7 patients with malignant melanoma of the conjunctiva or periocular skin and 1 patient with Merkel cell carcinoma of the eyelid. On lymphoscintigraphy, at least 1 SLN was identified in 7 of the 8 patients. Although all lesions located in the lateral half of the ocular adnexa drained to at least one SLN in the parotid (preauricular) area, there was some variability in the drainage patterns of lesions located in the medial half of the ocular adnexa. A smaller injection volume (0.2 mL) was adequate for detecting the nodes draining the area of injection and led to less spread of technetium to the surrounding areas. Six patients underwent SLN biopsy. In all but one, the nodes identified during surgery corresponded with those visualized on lymphoscintigraphy.
Preoperative lymphoscintigraphy successfully identifies SLNs in most patients with conjunctival and periocular skin malignancies. Smaller injection volumes (0.2 mL) appear to be adequate for identification of the sentinel nodes and lead to less spread to surrounding tissues.
确定术前淋巴闪烁造影术用于识别结膜及眼周皮肤肿瘤患者前哨淋巴结(SLN)的可行性,并确定此类肿瘤的淋巴引流模式。
我们回顾性分析了1999年1月至2000年6月期间所有经活检确诊为结膜及眼周皮肤恶性肿瘤且接受了淋巴闪烁造影术(无论是否进行SLN活检)的患者记录。患者接受了0.3至1毫居里的锝Tc-99m硫胶体注射,注射体积为0.2毫升或1毫升。一旦通过摄像头检测到首个SLN,即刻拍照,此后每15分钟拍照一次。除非患者拒绝或存在手术医学禁忌证,淋巴闪烁造影术后1至2天进行术中定位及SLN活检。
该研究纳入了7例结膜或眼周皮肤恶性黑色素瘤患者及1例眼睑默克尔细胞癌患者。在淋巴闪烁造影术中,8例患者中有7例至少识别出1个SLN。尽管所有位于眼附属器外侧半侧的病变均引流至腮腺(耳前)区域的至少1个SLN,但位于眼附属器内侧半侧的病变引流模式存在一定差异。较小的注射体积(0.2毫升)足以检测引流注射区域的淋巴结,并减少锝向周围区域的扩散。6例患者接受了SLN活检。除1例患者外,手术中识别出的淋巴结与淋巴闪烁造影术中显示的淋巴结相符。
术前淋巴闪烁造影术成功识别了大多数结膜及眼周皮肤恶性肿瘤患者的SLN。较小的注射体积(0.2毫升)似乎足以识别前哨淋巴结,并减少向周围组织的扩散。